Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Conclusions:
Natalizumab's effects on peripheral immune cells and pharmacodynamic markers were reversible, with changes starting 8 weeks post last natalizumab dose; levels returned to those observed/expected in untreated patients 16 weeks post last dose. This reversibility differentiates natalizumab from MS treatments that require longer reconstitution times. Characterization of the time course of natalizumab's biological effects may help clinicians make treatment sequencing decisions.

Classification of evidence:
This study provides Class III evidence that the pharmacodynamic markers of natalizumab are reversed 16 weeks after stopping natalizumab.

Source: Neurology - October 9, 2017 Category: Neurology Authors: Plavina, T., Muralidharan, K. K., Kuesters, G., Mikol, D., Evans, K., Subramanyam, M., Nestorov, I., Chen, Y., Dong, Q., Ho, P.-R., Amarante, D., Adams, A., De Seze, J., Fox, R., Gold, R., Jeffery, D., Kappos, L., Montalban, X., Weinstock-Guttman, B., Har Tags: All Demyelinating disease (CNS), Multiple sclerosis ARTICLE Source Type: research